Development of 3D human intestinal equivalents for substance testing in microliter-scale on a multi-organ-chip : From 23rd European Society for Animal Cell Technology (ESACT) Meeting: Better Cells for Better Health Lille, France. 23-26 June 2013

First published by BioMed Central: Jaenicke, Annika; Tordy, Dominique; Groeber, Florian; Hansmann, Jan; Nietzer, Sarah; Tripp, Carolin; Walles, Heike; Lauster, Roland; Marx, Uwe: Development of 3D human intestinal equivalents for substance testing in microliter-scale on a multi-organ-chip. - In: BMC Proceedings. - ISSN 1753-6561 (online). - 7 (2013), suppl. 6, P65. - doi:10.1186/1753-6561-7-S6-P65

Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models

To improve and focus preclinical testing, we combine tumor models based on a decellularized tissue matrix with bioinformatics to stratify tumors according to stage-specific mutations that are linked to central cancer pathways. We generated tissue models with BRAF-mutant colorectal cancer (CRC) cells (HROC24 and HROC87) and compared treatment responses to two-dimensional (2D) cultures and xenografts. As the BRAF inhibitor vemurafenib is—in contrast to melanoma—not effective in CRC, we combined it with the EGFR inhibitor gefitinib. In general, our 3D models showed higher chemoresistance and in contrast to 2D a more active HGFR after gefitinib and combination-therapy. In xenograft models murine HGF could not activate the human HGFR, stressing the importance of the human microenvironment. In order to stratify patient groups for targeted treatment options in CRC, an in silico topology with different stages including mutations and changes in common signaling pathways was developed. We applied the established topology for in silico simulations to predict new therapeutic options for BRAF-mutated CRC patients in advanced stages. Our in silico tool connects genome information with a deeper understanding of tumor engines in clinically relevant signaling networks which goes beyond the consideration of single drivers to improve CRC patient stratification

Gen-Umwelt-Interaktionen in Serotonin-Transporter-Knockout-Mäusen - Wie Stress die Genexpression und die neuronale Morphologie beeinflusst

Serotonin (5-HT) is an important modulator of many physiological, behavioural and developmental processes and it plays an important role in stress coping reactions. Anxiety disorders and depression are stress-related disorders and they are associated with a malfunction of the 5-HT system, in which the 5-HT transporter (5-HTT) plays an important role. 5-Htt knockout (KO) mice represent an artificially hyperserotonergic environment, show an increased anxiety-like behaviour and seem to be a good model to investigate the role of the 5-HT system concerning stress reactions and anxiety disorders. As synaptic proteins (SPs) seem to be involved in stress reactions, the effect of acute immobilization stress on the expression of the three SPs Synaptotagmin (Syt) I, Syt IV and Syntaxin (Stx) 1A was studied in the 5-Htt KO mouse model as well as the expression of the two immediate early genes (IEGs) FBJ osteosarcoma oncogene (c-Fos) and fos-like antigen 2 (Fra-2). Additionally, the expression of the corticotrophin releasing hormone (CRH) and its two receptors CRHR1 and CRHR2 was investigated as part of the hypothalamic-pituitary-adrenal (HPA) stress system. Based on gender- and genotype-dependent differences in corticosterone levels, expression differences in the brain were investigated by performing a quantitative real time-PCR study using primer pairs specific for these SPs and for the IEGs c-Fos and Fra-2 in five different brain regions in 5-Htt KO and 5-Htt wild-type (WT) mice. Mainly gender-dependent differences could be found and weaker stress effects on the expression of SPs could be demonstrated. Regarding the expression of IEGs, stress-, gender- and genotype-dependent differences were found mainly in the hypothalamus. Also in the hypothalamus, gender effects were found concerning the expression of CRH and its both receptors. Additionally, in a second study, male 5-Htt WT and male 5-Htt deficient mice were subjected to a resident-intruder-paradigm which stresses the animals through a loser experience. The morphological changes of neurons were subsequently analyzed in Golgi-Cox-stained sections of limbic brain areas in stressed and unstressed animals of both genotypes using the computer-based microscopy system Neurolucida (Microbrightfield, Inc.). While no differences concerning dendritic length, branching patterns and spine density were found in the hippocampus and no differences concerning dendritic length and branching patterns could be shown in the cingulate cortex (CG), pyramidal neurons in the infralimbic cortex (IL) of stressed 5-Htt WT mice displayed longer dendrites compared to unstressed 5-Htt WT mice. The results indicate that, although in this model drastic alterations of neuronal morphology are absent, subtle changes can be found in specific brain areas involved in stress- and anxiety-related behaviour which may represent neural substrates underlying behavioural phenomena.Serotonin (5-HT) ist ein wichtiger Modulator vieler physiologischer, verhaltensbiologischer und entwicklungsbiologischer Vorgänge und spielt zudem eine wichtige Rolle bei der Stressbewältigung. Angsterkrankungen und Depression sind stressbedingte Störungen und sie sind mit einer Dysfunktion des serotonergen Systems assoziiert, in dem der Serotonintransporter (5-HTT) eine wichtige Funktion einnimmt. 5-Htt Knockout (KO)-Mäuse haben reduzierte Serotoninkonzentrationen im Gehirn, zeigen erhöhtes Angst-ähnliches Verhalten und scheinen ein gutes Modell für die Erforschung der Rolle des serotonergen Systems in Bezug auf Stress-Reaktionen und Angsterkrankungen darzustellen. Da synaptische Proteine (SPs) in die Stress-Reaktion involviert zu sein scheinen, wurden die Auswirkungen von akutem Immobilizierungsstress auf die Expression der drei SPs Synaptotagmin (Syt) I, Syt IV und Syntaxin (Stx) 1A in diesem 5-Htt KO-Maus-Modell untersucht. Ebenso wurde die Expression der zwei „immediate early genes“ (IEGs) FBJ osteosarcoma oncogene (c-Fos) and fos-like antigen 2 (Fra-2) unter die Lupe genommen. Außerdem wurde die Expression des „Corticotrophin Releasing Hormone“ (CRH) sowie seiner beiden Rezeptoren CRHR1 and CRHR2, als Teil des Hypothalamus- Hypophysen-Nebennieren-(HPA)-Systems, analysiert. Basierend auf Geschlechts- und Genotyp-spezifischen Unterschieden der Kortikosteron-Konzentrationen im Blut der Tiere wurden die Expressionslevel dieser SPs und der beiden IEGs mittels quantitativer Real-Time (qRT)-PCR in fünf verschiedenen Gehirnregionen von 5-Htt KO- und 5-Htt-Mäusen mit wildtypischer (WT) Gen-Konstitution untersucht. Dabei konnten vor allem Geschlechts-spezifische Unterschiede in der Genexpression gezeigt werden und es konnte ein im Vergleich dazu schwächerer Einfluss des akuten Immobilisierungs-Stresses auf die Genexpression nachgewiesen werden. Die Expression der IEGs wurde durch Stress, Geschlecht und Genotyp vor allem im Hypothalamus beeinflusst. Ebenfalls im Hypothalamus konnte der Einfluss des Geschlechts auf die Expression des CRH und seiner beiden Rezeptoren gezeigt werden. In einer zweiten Studie wurden männliche 5-Htt KO-Mäuse sowie 5-Htt WT-Mäuse dem „Resident-Intruder-Paradigma“ unterzogen, in welchem die Tiere mittels einer mehrfachen Verlierer-Erfahrung gestresst wurden. Morphologische Veränderungen von Neuronen limbischer Gehirnareale wurden daraufhin an Golgi-Cox-gefärbten Gehirnschnitten dieser gestressten und ungestressten 5-Htt KO- und 5-Htt WT-Tiere mittels des Computer-gestützten Mikroskop-Systems Neurolucida (Microbrightflield, Inc.) analysiert. Während keine Unterschiede bezüglich der Länge des dendritischen Materials, des Verzweigungsmusters und der Spinedichte im Hippocampus gefunden werden konnten und keine Unterschiede in Länge des dendritischen Materials und des Verzweigungsmusters in der Area cinguli (CG) gezeigt werden konnten, wiesen Pyramidenzellen im infralimbischen Kortex (IL) von gestressten 5-Htt WT-Mäusen längere Dendriten auf als die entsprechenden Zellen in den ungestressten Tieren desselben Genotyps. Diese Ergebnisse zeigen, dass, obwohl in diesen Tieren keine drastischen stressbedingten Änderungen der neuronalen Morphologie vorliegen, doch subtile Änderungen der neuronalen Morphologie stress- und angstinvolvierter Gehirnareale gefunden werden können. Diese Änderungen können die neuronale Basis verschiedenster Verhaltens-Phänomene darstellen

MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact

MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

BackgroundImmunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both in the pre-clinical and clinical setting. A perceived barrier to the efficacy of CAR T-cell therapy in solid tumors is the hostile tumor microenvironment where immunosuppressive soluble factors like transforming growth factor (TGF)-β are thought to inhibit the cellular immune response. Here, we analyzed whether CAR T-cells specific for the receptor tyrosine kinase-like orphan receptor 1 (ROR1) antigen, that is frequently expressed in triple-negative breast cancer (TNBC), are susceptible to inhibition by TGF-β and evaluated TGF-β-receptor signaling blockade as a way of neutralizing the inhibitory effect of this cytokine.MethodsCD8+ and CD4+ ROR1-CAR T-cells were prepared from healthy donors and their antitumor function analyzed using the TNBC cell line MDA-MB-231 in vitro and in a microphysiologic 3D tumor model. Analyses were performed in co-culture assays of ROR1-CAR T-cells and MDA-MB-231 cells with addition of exogenous TGF-β.ResultsThe data show that exposure to TGF-β engages TGF-β-receptor signaling in CD8+ and CD4+ ROR1-CAR T-cells as evidenced by phosphorylation of small mothers against decapentaplegic homolog 2. In the presence of TGF-β, the cytolytic activity, cytokine production and proliferation of ROR1-CAR T-cells in co-culture with MDA-MB-231 TNBC cells were markedly impaired, and the viability of ROR1-CAR T-cells reduced. Blockade of TGF-β-receptor signaling with the specific kinase inhibitor SD-208 was able to protect CD8+ and CD4+ ROR1-CAR T-cells from the inhibitory effect of TGF-β, and sustained their antitumor function in vitro and in the microphysiologic 3D tumor model. Combination treatment with SD-208 also led to increased viability and lower expression of PD-1 on ROR1-CAR T-cells at the end of the antitumor response.ConclusionWe demonstrate the TGF-β suppresses the antitumor function of ROR1-CAR T-cells against TNBC in preclinical models. Our study supports the continued preclinical development and the clinical evaluation of combination treatments that shield CAR T-cells from TGF-β, as exemplified by the TGF-β-receptor kinase inhibitor SD-208 in this study

A combined tissue‐engineered/in silico signature tool patient stratification in lung cancer

Patient‐tailored therapy based on tumor drivers is promising for lung cancer treatment. For this, we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations, we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We improve in vitro models of tissue conditions by a biological matrix‐based three‐dimensional (3D) tissue culture that allows in vitro drug testing: It correctly shows a strong drug response upon gefitinib (Gef) treatment in a cell line harboring an EGFR‐activating mutation (HCC827), but no clear drug response upon treatment with the HSP90 inhibitor 17AAG in two cell lines with KRAS mutations (H441, A549). In contrast, 2D testing implies wrongly KRAS as a biomarker for HSP90 inhibitor treatment, although this fails in clinical studies. Signaling analysis by phospho‐arrays showed similar effects of EGFR inhibition by Gef in HCC827 cells, under both 2D and 3D conditions. Western blot analysis confirmed that for 3D conditions, HSP90 inhibitor treatment implies different p53 regulation and decreased MET inhibition in HCC827 and H441 cells. Using in vitro data (western, phospho‐kinase array, proliferation, and apoptosis), we generated cell line‐specific in silico topologies and condition‐specific (2D, 3D) simulations of signaling correctly mirroring in vitro treatment responses. Networks predict drug targets considering key interactions and individual cell line mutations using the Human Protein Reference Database and the COSMIC database. A signature of potential biomarkers and matching drugs improve stratification and treatment in KRAS‐mutated tumors. In silico screening and dynamic simulation of drug actions resulted in individual therapeutic suggestions, that is, targeting HIF1A in H441 and LKB1 in A549 cells. In conclusion, our in vitro tumor tissue model combined with an in silico tool improves drug effect prediction and patient stratification. Our tool is used in our comprehensive cancer center and is made now publicly available for targeted therapy decisions

A combined tissue-engineered/in silico signature tool patient stratification in lung cancer

Patient‐tailored therapy based on tumor drivers is promising for lung cancer treatment. For this, we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations, we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We improve in vitro models of tissue conditions by a biological matrix‐based three‐dimensional (3D) tissue culture that allows in vitro drug testing: It correctly shows a strong drug response upon gefitinib (Gef) treatment in a cell line harboring an EGFR‐activating mutation (HCC827), but no clear drug response upon treatment with the HSP90 inhibitor 17AAG in two cell lines with KRAS mutations (H441, A549). In contrast, 2D testing implies wrongly KRAS as a biomarker for HSP90 inhibitor treatment, although this fails in clinical studies. Signaling analysis by phospho‐arrays showed similar effects of EGFR inhibition by Gef in HCC827 cells, under both 2D and 3D conditions. Western blot analysis confirmed that for 3D conditions, HSP90 inhibitor treatment implies different p53 regulation and decreased MET inhibition in HCC827 and H441 cells. Using in vitro data (western, phospho‐kinase array, proliferation, and apoptosis), we generated cell line‐specific in silico topologies and condition‐specific (2D, 3D) simulations of signaling correctly mirroring in vitro treatment responses. Networks predict drug targets considering key interactions and individual cell line mutations using the Human Protein Reference Database and the COSMIC database. A signature of potential biomarkers and matching drugs improve stratification and treatment in KRAS‐mutated tumors. In silico screening and dynamic simulation of drug actions resulted in individual therapeutic suggestions, that is, targeting HIF1A in H441 and LKB1 in A549 cells. In conclusion, our in vitro tumor tissue model combined with an in silico tool improves drug effect prediction and patient stratification. Our tool is used in our comprehensive cancer center and is made now publicly available for targeted therapy decisions

Tissue Engineering of a Human 3D in vitro Tumor Test System

Cancer is one of the leading causes of death worldwide. Current therapeutic strategies are predominantly developed in 2D culture systems, which inadequately reflect physiological conditions in vivo. Biological 3D matrices provide cells an environment in which cells can self-organize, allowing the study of tissue organization and cell differentiation. Such scaffolds can be seeded with a mixture of different cell types to study direct 3D cell-cell-interactions. To mimic the 3D complexity of cancer tumors, our group has developed a 3D in vitro tumor test system. Our 3D tissue test system models the in vivo situation of malignant peripheral nerve sheath tumors (MPNSTs), which we established with our decellularized porcine jejunal segment derived biological vascularized scaffold (BioVaSc). In our model, we reseeded a modified BioVaSc matrix with primary fibroblasts, microvascular endothelial cells (mvECs) and the S462 tumor cell line For static culture, the vascular structure of the BioVaSc is removed and the remaining scaffold is cut open on one side (Small Intestinal Submucosa SIS-Muc). The resulting matrix is then fixed between two metal rings (cell crowns). Another option is to culture the cell-seeded SIS-Muc in a flow bioreactor system that exposes the cells to shear stress. Here, the bioreactor is connected to a peristaltic pump in a self-constructed incubator. A computer regulates the arterial oxygen and nutrient supply via parameters such as blood pressure, temperature, and flow rate. This setup allows for a dynamic culture with either pressure-regulated pulsatile or constant flow. In this study, we could successfully establish both a static and dynamic 3D culture system for MPNSTs. The ability to model cancer tumors in a more natural 3D environment will enable the discovery, testing, and validation of future pharmaceuticals in a human-like model